Krithika Subramanian

Krithika Subramanian

Auto-generated profile, based on publicly available information

Krithika Subramanian

Centre for Brain Research (CBR), Bengaluru, India. Manipal Academy of Higher Education (MAHE), Karnataka, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KSKrithika Subramanian
Krithika Subramanian
CBChandrika Bhattacharyya
Chandrika Bhattacharyya
PMPratheusa Machha
Pratheusa Machha
AMAnkit Mukherjee
Ankit Mukherjee
DTDevashish Tripathi
Devashish Tripathi
ABAnalabha Basu
Analabha Basu
India, the most populous country, remains significantly underrepresented in the global genomics landscape. Previous efforts to catalog Indian genetic diversity were limited in scale, scope, and representation. Here, we present the GenomeIndia dataset, comprising whole genome sequences of 9,768 healthy individuals from 83 populations spanning the ethnolinguistic and biogeographic spectrum of India. We identify 129.93 million high-confidence biallelic variants, 44.03 million of which are previously unreported in global databases. In contrast to large populations that show steady population growth and internal homogeneity, we observe low effective population sizes, significant genetic drift, and profound homozygosity in small tribal groups, likely shaped by antiquity, isolation, and endogamy. We report multiple population-specific pharmacogenomic and deleterious variants, necessitating the integration of local genetic architecture and the inclusion of underrepresented South Asian genomes in global reference resources. Finally, we highlight the limited transferability of Eurocentric polygenic scores to Indian populations, and present an imputation panel that outperforms existing resources for both rare and common variants. Together, our work fills a significant gap in the equity of global human genomics, and paves way for precision medicine strategies that will benefit a quarter of the world population.